Dwight Moxie - Mar 15, 2022 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Signature
/s/ Terri McDowell, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Mar 15, 2022
Transactions value $
-$80,687
Form type
4
Date filed
3/17/2022, 05:52 PM
Previous filing
Feb 4, 2022
Next filing
Sep 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Tax liability -$45.5K -2.88K -6.03% $15.79 44.9K Mar 15, 2022 Direct F1
transaction RVNC Common Stock Tax liability -$35.2K -2.23K -4.96% $15.79 42.7K Mar 15, 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 25,000 shares. The RSA vests in three equal annual installments from March 15, 2020, subject to Mr. Moxie's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date.
F2 Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSA for 19,346 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Moxie's Continuous Service (as defined in the Plan) on each vesting date.